en · de · es · fr · pt
tb-500-notes.peptides4800.com › Blog › Identity And Research Background — What the Evidence Shows

Identity And Research Background — What the Evidence Shows

By Editorial Desk · published 2025-11-04 · last reviewed 2025-11-19 · Blog

The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.

Identity and Research Background

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

Thymosin Beta-4 Fragment Identity

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

Handling, Storage, and Analytical Verification

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Related pages on this site

Handling, Storage, and Quality Control

Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.

Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.

Identity and Reported Background

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

Reference notes

=== Guatemala === The URNG condemned the US military action and demanded the withdrawal of the US forced from the region and the release of Maduro. Winaq condemned the US military action saying it was not "to the defense of democracy or human rights, but to the historical interests of imperialism to appropriate the strategic resources of the people".

Necrophages and their microbiotas ("friendly bacteria") produce several molecules of medical interest. These include molecules that can bind to bacterial pathogens (e.g. lectins), inhibit pathogen growth (e.g. chitin, cyclic lipopeptides), and kill pathogens (e.g. antimicrobial peptides, lysozymes). In nature, these molecules are thought to block pathogen entry into the integuments (e.g. skin, cuticle) and circulatory systems (e.g. blood, hemolymph) of necrophages, and enable the immune systems of necrophages to detect, inhibit and kill any pathogens that breach these barriers. Research is underway in Germany, China, the USA and other countries to develop these molecules for use in medicine. Possible applications include antimicrobial wound dressings, antibacterial drugs, and drug delivery systems for bacterial infections.

=== Autism === An intranasal formulation of carbetocin was also under development for the treatment of autism, but development was discontinued as well. It was variously developed by Nastech Pharmaceutical Company, Retrophin (Travere Therapeutics), Marina Biotech, and Cypress Bioscience and had the developmental code name CYP-2001. The drug reached phase 1 trials for autism prior to being discontinued.

Sources: en.wikipedia.org

Reference notes

In other words, the lack of positive support and validation increases the risk for divorce. Because of the expansive research done on the significance of social support within a marriage, it is important to understand that this research was inspired by a theory called the attachment theory perspective. Attachment theory stresses the importance of support and care giving in a relationship for the development of trust and security. Attachment theory, as conceptualized by Collins and Feeney (2000) is an interpersonal, transactional process that involves one partners caregiving responses.

== Animal feed == FDA permits a certain amount of cyanuric acid to be present in some non-protein nitrogen (NPN) additives used in animal feed and drinking water. Cyanuric acid has been used as NPN. For example, Archer Daniels Midland manufactures an NPN supplement for cattle, which contains biuret, triuret, cyanuric acid and urea.

==== Heliscope single molecule sequencing ==== Heliscope sequencing is a method of single-molecule sequencing developed by Helicos Biosciences. It uses DNA fragments with added poly-A tail adapters which are attached to the flow cell surface. The next steps involve extension-based sequencing with cyclic washes of the flow cell with fluorescently labeled nucleotides (one nucleotide type at a time, as with the Sanger method). The reads are performed by the Heliscope sequencer. The reads are short, averaging 35 bp. What made this technology especially novel was that it was the first of its class to sequence non-amplified DNA, thus preventing any read errors associated with amplification steps. In 2009 a human genome was sequenced using the Heliscope, however in 2012 the company went bankrupt.

Sources: en.wikipedia.org

Reference notes

=== Dynamic covalent chemistry === In dynamic covalent chemistry covalent bonds are broken and formed in a reversible reaction under thermodynamic control. While covalent bonds are key to the process, the system is directed by non-covalent forces to form the lowest energy structures.

== Functions == The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This growth factor is a high affinity, heparin dependent ligand for FGFR4. Expression of this gene was detected only in fetal but not adult brain tissue. Synergistic interaction of the chick homolog and Wnt-8c has been shown to be required for initiation of inner ear development. The orthologous protein in mouse is FGF15, which shares about 50% amino acid identity and has similar functions. Together they are often referred to as FGF15/19. FGF19 has important roles as a hormone produced in the ileum in response to bile acid absorption. Bile acids bind to the farnesoid X receptor (FXR), stimulating FGF19 transcription. Several FXR / bile acid response elements have been identified in the FGF19 gene. Human FGF19 transcripts have been shown to be stimulated approximately 300-fold by physiological concentrations of bile acids including chenodeoxycholic acid, glycochenodeoxycholic acid and obeticholic acid in explants of ileal mucosa. FGF19 regulates new bile acid synthesis, acting through the FGFR4/Klotho-β receptor complexes in the liver to inhibit CYP7A1. FGF19 also has metabolic effects, affecting glucose and lipid metabolism when used in experimental mouse models.

=== Ocular myxoma === Myxoma is a rare, benign stromal tumor of mesenchymal origin often confused with other conjunctival stromal tumors. Conjunctival myxomas are thought to originate in Tenon's capsule and can masquerade as conjunctival lymphoma, lymphangioma, ocular surface squamous neoplasia (OSSN), or amelanotic melanoma.

== Dating with decay products of short-lived extinct radionuclides == Absolute radiometric dating requires a measurable fraction of parent nucleus to remain in the sample rock. For rocks dating back to the beginning of the Solar System, this requires extremely long-lived parent isotopes, making measurement of such rocks' exact ages imprecise. To be able to distinguish the relative ages of rocks from such old material, and to get a better time resolution than that available from long-lived isotopes, short-lived isotopes that are no longer present in the rock can be used. At the beginning of the solar system, there were several relatively short-lived radionuclides like 26Al, 60Fe, 53Mn, and 129I present within the solar nebula. These radionuclides—possibly produced by the explosion of a supernova—are extinct today, but their decay products can be detected in very old material, such as that which constitutes meteorites. By measuring the decay products of extinct radionuclides with a mass spectrometer and using isochronplots, it is possible to determine relative ages of different events in the early history of the solar system. Dating methods based on extinct radionuclides can also be calibrated with the U–Pb method to give absolute ages. Thus both the approximate age and a high time resolution can be obtained. Generally a shorter half-life leads to a higher time resolution at the expense of timescale.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Network